electroCore Dividend

Dividend criteria checks 0/6

electroCore does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	1.8%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$3.14
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

electroCore (NASDAQ:ECOR) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jan 07

electroCore gains on distribution deal for gammaCore Sapphire in Eastern Europe

Dec 22

electroCore shares jump 9% on positive results in migraine prevention study

Dec 08

electroCore (ECOR) Investor Presentation - Slideshow

Nov 20

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ECOR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ECOR's dividend payments have been increasing.

Dividend Yield vs Market

electroCore Dividend Yield vs Market

How does ECOR dividend yield compare to the market?
Segment	Dividend Yield
Company (ECOR)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Medical Equipment)	1.8%
Analyst forecast in 3 Years (ECOR)	n/a

Notable Dividend: Unable to evaluate ECOR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ECOR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ECOR's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ECOR has not reported any payouts.

electroCore Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024

electroCore, Inc. Announces Results of Truvaga Plus Consumer Study

electroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness

electroCore, Inc. to Report Q4, 2023 Results on Mar 13, 2024

electroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the Board

Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation (Nvns) for Treatment of Symptoms of Gastroparesis

electroCore, Inc. to Report Q3, 2023 Results on Nov 08, 2023

electroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress Disorder

electroCore, Inc. Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering

electroCore, Inc. Reiterates Revenue Guidance for the Year 2023

electroCore, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Electrocore Provides Earnings Guidance for the Second Quarter and Full Fiscal Year 2023

electroCore, Inc., Annual General Meeting, Aug 04, 2023

electroCore, Inc. Reiterates Revenue Guidance for the Year Ending December 31, 2023

electroCore, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2022

electroCore Receives a Determination Letter from Nasdaq Regarding Minimum Bid Price

electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga

electroCore, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

electroCore, Inc. to Report Q3, 2022 Results on Nov 03, 2022

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore sees Q3 revenue below consensus

electroCore is issued 4 new U.S. patents in nVNS therapy

electroCore, Inc., Annual General Meeting, Dec 02, 2022

electroCore, Inc. Announces Publication of a Peer Reviewed Manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore, Inc. to Report Q2, 2022 Results on Aug 04, 2022

electroCore, Inc. Provides Preliminary Unaudited Earnings Guidance for the Second Quarter of 2022

electroCore sees Q2 revenue estimate higher than consensus

Electrocore, Inc. Announces Study of Gammacore Sapphire™ for the Treatment of Post-Covid Syndrome

electroCore Announces Listing Transfer to the Nasdaq Capital Market

Co-Founder recently bought US$56k worth of stock

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2022

We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth

High number of new directors

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

electroCore, Inc. Provides Unaudited Preliminary Revenue Guidance for the First Quarter of 2022

High number of new directors

Consensus EPS estimates fall by 11%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Price target decreased to US$2.80

electroCore, Inc. to Report Q4, 2021 Results on Mar 10, 2022

electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus

electroCore, Inc. Provides Revenue Guidance for the Full Year of 2021

electroCore, Inc. Announces Publication of Premium II Trial of Gammacore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of Migraine

electroCore: Pioneering Bioelectronic Medicine

Third quarter 2021 earnings released: US$0.057 loss per share (vs US$0.10 loss in 3Q 2020)

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

Second quarter 2021 earnings released: US$0.06 loss per share (vs US$0.13 loss in 2Q 2020)

Consensus forecasts updated

electroCore, Inc. Announces Revenue Guidance for the Second Quarter of 2021

electroCore, Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

electroCore completes sale of $1.4M of NOL tax benefits

electroCore, Inc. Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’S Disease Patients

electroCore, Inc. Develops Non-Drug and Non-Invasive Alternative to Pharmaceuticals That Safely and Effectively Stimulates the Vagus Nerve to Communicate with the Brain and Help Optimize the Body’s Own Ability to Control Problems Impacting Its Health

Price target decreased to US$3.50

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.27 loss in 1Q 2020)

electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2021

electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders

ElectroCore, Inc. Provides Revenue Guidance for the First Quarter of 2020

electroCore, Inc. to Report Q4, 2020 Results on Mar 11, 2021

electroCore, Inc. Announces Exclusive Distribution Agreement with Medistar2 PTY Limited Following Regulatory Approval in Australia

Non-Invasive Vagus Nerve Stimulation (Nvns) Enters New Stage of Covid-19 Research of electrocore, Inc

Do Institutions Own electroCore, Inc. (NASDAQ:ECOR) Shares?

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Adolescent Migraine

electroCore, Inc. Announces Completion of Enrollment in SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in COVID-19 Patients Exhibiting Respiratory Symptoms

Electrocore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (Nvns) to Reduce Ileus After Major Colorectal Surgery

electroCore Announces Full Enrollment of TR-VENUS study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Acute Treatment of Stroke

electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada

New 90-day high: US$1.90

electroCore expects FY20 revenue at upper end of $3.3M to $3.5M

electroCore (NASDAQ:ECOR) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Price target lowered to US$3.50